Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Portal hypertension develops in patients with advanced chronic liver diseases (CLD), especially cirrhosis and is associated with complications of the disease, such as gastrointestinal bleeding and ascites resulting in high mortality rates. The transjugular intrahepatic portosystemic shunt (TIPS) is one of the treatment options for portal hypertension, aiming to decrease portal venous pressure by establishing an artificial passage for blood from the gastrointestinal tract directly to the liver vein. This study focuses on the differences in the molecular composition of plasma samples from patients with portal hypertension before and after TIPS intervention to identify and characterise mediators influencing gut-liver cross-talk.
The plasma of 23 patients suffering from advanced CLD with portal hypertension was collected from peripheral veins before and after TIPS treatment and analysed using a well-established non-targeted chromatography-mass spectrometric (LC-MS) approach. In peripheral blood, the proteomic approach identified eleven biomolecules in the molecular range of 100 to 1,500 (m/z) with concentration differences induced by the TIPS intervention. The identified biomolecules were sequenced through MS/MS mass-spectrometry and analysed through literature mining to gain insight into their function and how they impact liver homeostasis.
Peptides originating from the parent proteins: sialomucin core protein 24 (CD164), meckelin, Histone-lysine N-methyltransferase (MLL3) and transient receptor potential cation channel subfamily V member 5 (TRPV5) were identified to be downregulated after the TIPS treatment. Similarly, the metabolites: 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF), uric acid, Dopamine, homoarginine, leucylproline and 5-methyluridine were significantly decreased after TIPS, whereas one yet unidentified low molecular-weight metabolite showed an increase after the medical procedure.
In conclusion, we identified novel biomarker candidates for portal hypertension in patients with CLD, with mechanistic clues of involvement in regulating pathological gut-liver cross-talk.
